WallSt.net (www.wallst.net ) Updates the Investment Community Through All-New Interviews with BPA, PPCO and NVAX

NEW YORK, July 10  /PRNewswire/ -- On June 19, Stephen Simes, CEO of Biosante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/ ) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:

  -- the company's "wide portfolio" of hormone therapy products
  -- size of the company's target markets, and market opportunities for the
     company's gel formulations
  -- hormone therapy products in development
  -- reasons the company's transdermal products have a competitive edge
  -- upcoming milestones for investors to watch for



To hear the interview in its entirety, and to read an in-depth report on the company, visit http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=bpa

On June 29, Jennifer Good, President CEO of Penwest Pharmaceuticals Co. (NASDAQ:PPCO) (http://www.penw.com/) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:

  -- reasons the company is going through a "bit of a transition"
  -- why Opana ER "has a lot of earnings leverage for Penwest"
  -- the company's relationship with Endo Pharmaceuticals, Inc.
  -- the company's three-pronged strategy to build its pipeline
  -- building a specialty sales force in neurology
  -- industry trends bolstering the company's growth prospects
  -- upcoming milestones for investors to watch for



To hear the interview in its entirety, visit http://www.wallst.net/audio/audio.asp?ticker=PPCO&id=3565

On June 20, Dr. Rahul Singhvi, President and CEO of Novavax, Inc. (NASDAQ:NVAX) (http://www.novavax.com/ ) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:

  -- reasons the company is "very well positioned to be a major vaccine
     player"
  -- commercial opportunities for the company's virus-like-particle approach
     to vaccine development
  -- initial targets for vaccine development
  -- development of the company's Avian Flu vaccine candidate
  -- proven track record of virus-like-particle-based drugs
  -- upcoming development milestones for investors to watch for



To hear the interview in its entirety, and to read an in-depth article on the company, visit http://www.wallst.net/editorials/article.asp?id=731

About WallSt.net:

http://www.wallst.net/ is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com/). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net/, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com/), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com/), a business and finance podcast Web site. We have received nine thousand nine hundred ninety five dollars from Biosante Pharmaceuticals, Inc. for media and advertising services. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .

(Logo:  http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO) 

http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO

http://photoarchive.ap.org/

DATASOURCE: WallStreet Direct, Inc.



CONTACT:  Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALLST



Web site:  http://www.biosantepharma.com/

http://www.wallst.net/

http://www.penw.com/

http://www.novavax.com/ 

Copyright